Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2003-05-29
2008-07-29
Zara, Jane (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S091100, C435S091310, C435S375000, C435S455000, C435S458000, C514S001000, C536S023100, C536S024500
Reexamination Certificate
active
07405205
ABSTRACT:
Compounds and methods for modulating cell proliferation, preferably inhibiting the proliferation of tumor cells are described. Compounds that may be used to modulate cell proliferation include antisense oligonucleotides complementary to regions of the mammalian ribonucleotide reductase genes.
REFERENCES:
patent: 5023252 (1991-06-01), Hseih
patent: 5034506 (1991-07-01), Summerton et al.
patent: 5225347 (1993-07-01), Goldberg et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5719262 (1998-02-01), Buchardt et al.
patent: 5766855 (1998-06-01), Buchardt et al.
patent: 5834279 (1998-11-01), Rubin et al.
patent: 5998383 (1999-12-01), Wright et al.
patent: 6121000 (2000-09-01), Wright et al.
patent: 2006/0241070 (2006-10-01), Wright et al.
patent: 0383190 (1990-08-01), None
patent: WO 94/21661 (1994-09-01), None
patent: WO 95/02069 (1995-01-01), None
patent: WO 98/00532 (1998-01-01), None
patent: WO 98/05769 (1998-12-01), None
patent: WO 99/02673 (1999-01-01), None
patent: WO 99/02673 (1999-01-01), None
Agrawal et al., (1995)Oncogen, 11:427-438.
Agrawal (1996) “Antisense oligonucleotides: Towards clinical trials,”TIBTECH, 14: 376-387.
Akhter et al., (1991) “Interactions of antisense DNA oligonucleotide analogs with phospholipid membrandes (liposomes),”Nucleic Acids Res., 19: 5551-5559.
Alessi et al., (1995)Meth Enzymol., 255:279-290.
Altschul, S.F. et al., (1990) “Basic local alignment search tool,”J. Mol. Biol., 215:403-410.
Amara et al., (1994) “Phorbol ester modulation of a novel cytoplasmic protein binding activity at the 3′-untranslated region of mammalian ribonucleotide reductase R2 mRNA and role in message stability.”J. Biol. Chem.269:6709-7071.
Amara et al., (1995) “Defining a novelciselement in the 3′-untranslated region of mammalian ribonucleotide reductase component R2 mRNA: Role in transforming growth factor-beta1inducted mRNA stabilization.”Nucleic Acids Res. 23:1461-1467.
Amara et al., (1996) “Defining a novelciselement in the 3′-untranslated region of mammalian ribonucleotide reductase component R2 Mrna:cis-transinteractions and message stability.”J. Biol. Chem.271:20126-20131.
Anazodo et al., (1995) “Sequence-specific inhibition of gene expression by a novel antisense oligodeoxynucleotide phosphorothioate directed against a nonregulatory region of the human immunodeficiency virus type 1 genome.”J. Virol. 69:1794-1801.
Anazodo et al., (1996) “Relative levels of inhibition of p24 gene expression by different 20-mer antisense oligonucleotide sequences targeting nucleotides + 1129 to +1268 of the HIV-1 gag genome: An analysis of mechanism,”Biochem. Biophys. Res. Commun.229:305-309.
Ashihara et al., (1979) “Cell Synchronization,”Methods Enzymol., 58:248-262.
Barker, R.H. Jr., et al. (1996) “Inhibition of plasmodium falcipanum malaria using antisense oligodeoxynucleotides,”Proc. Natl. Acad. Sci. USA, 93(1):514-518.
Bjorklund et al., (1993) “Structure and promoter characterization of the gene encoding the large subunit (R1 Protein) of mouse ribonucleotide reductase.”Proc. Natl. Acad. Sci. USA,90:11322-11326.
Bjorklund, S., et al., (1990) “S-phase-specific expression of mammalian ribonucleotide reductase R1 and R2 subunit mRNAs,”Biochemistry, 29(23):5452-5458.
Blaesse (1997) “Gene therapy for cancer,”Scientific American, 276(6):111-115.
Blin et al., (1976) “A general method of isolation of high molecular weight DNA from cukaryotes,”Nucleic Acids Res., 3:2303-2308.
Blosmanis et al., (1987)Cancer Res., 47:1273-1277.
Boven et al., (1992) “Phase II preclinical drug screening in human tumor xenografts: A first European multicenter collaborative study.”Cancer Res., 52:5940-5947.
Bradley et al., (1986)Proc. Natl. Acad. Sci. USA, 83:5277-5281.
Branch, (1998)TIBS, 23:45-50.
Brower et al. (1998) “All clear for HIV-targeting ribozyme in phase II,”Nature Biotechnology, 16(2):123.
Calabretta et al., (1996) “Antisense strategies in the treatment of leukemias,”Semin. Oncocol, 23:78.
Caras, (1985) “Cloned mouse ribonucleotide reductase subunit M1 cDNA reveals amino acid sequence homology withEscherichia coliand herpes virus ribonucleotide reductases,”Biol Chem., 260:7015-7022.
Chadee et al., (1995)J. Biol. Chem., 270:20098-20105.
Chakrabarti, D., et al., (1993) “Cloning and characterization of subunit genes of ribonucleotide reductase, a cell-cycle-regulated enzyme, fromPlasmodium falcipanum,” Proc. Natl. Acad. Sci. USA, 90:12020-12024.
Chan et al., (1993)Biochemistry, 32:12835-12840.
Chang et al., (1978) “Phenotypic expression ine- coliof a DNA sequence coding for mouse dihydrofolate reductase,”Nature, 275:617-624.
Chaudhuri, M.M., et al., (1992) “cDNA sequence of the small subunit of the hamster ribonucleotide reductase,”Biochimion et Biophysica Acta, 1171:117-121.
Chen et al., (1993) “Mammalian ribonucleotide reductase R1 mRNA stability under normal and phorbol ester stimulating conditions: Involvement of acis-transinteraction at the 3′-untranslated region,”EMBO J., 12:3977-3986.
Chen et al., (1994) “Defining a novel ribonucleotide reductase R1 mRNAciselement that binds to an unique cytoplasmic trans-acting protein,”Nucleic Acids Res., 22:4796-4797.
Choy et al., (1998) “Molecular mechanisms of drug resistance involving ribonucleotide reductase: Hydroxyurea resistance in a series of clonally related mouse cell lines selected in the presence of increasing drug concentrations,”Cancer Res., 48:2029-2035.
Choy et al., (1989)Biochem. Biophys. Res. Commun., 162:1417-1424.
Cole et al. (1992) “Over expression of a transporter gene is a multidrug-resistant human lung cancer cell line,”Science, 258:1650-1654.
Cregg, J.M. et al., (1993) “Recent advances in the expression of foreign genes inpichia pastoris,” Bio/Technology, 11:905-910.
Crooke, (1995) “Progress in antisense therapeuties,”Hematol. Pathol., 2:59-72.
Damen et al., (1989) “Generation of metastatic variants in populations of mutator and amplificator mutants,”J. Natl. Cancer Inst., 81:628-631.
Damen et al., (1991) “Transformation and amplification of the K-fgf Protooncogene in NIH-3T3 cells, and induction of metastatic potential,”Biochem Biopys. Acta,1097:103-110.
Davis et al., (1994) “Purification, characterization, and localization of subunit interaction area of recombinant mouse ribonucleotide reductase R1 subunit,”Biol. Chem., 269:23171-23176.
Devereux, J., et al., (1984) “A comprehensive set of sequence analysis programs for the VAX,”Nucleic Acids Res., 12:387-395.
Eckstein, (1985) “Nucleoside Phosphorothioates,”Ann. Rev. Biochem. 54:367-402.
Edwards, et al., (1985)Mol. Cell. Biol., 5:3280-3288.
Egan, et al., (1987) “Expression of H-rascorrelates with metastatic potential: Evidence for direct regulation of the metastatic phenotype in 10T1/2 and NIH 3T3 cells,”Mol. Cell. Biol., 7:830-837.
Egan et al., (1987) “Transformation by oncogenes encoding protein kinases induces the metastatic pheonotype.”Science, 238:202-205.
Eriksson et al., (1984) “Cell cycle-dependent regulation of mammalian ribonucleotide reductase: The S phase-correlated increase in subunit M2 is regulated byde novoprotein synthesis,”J. Biol. Chem. 259:11695-11700.
Fan et al., (1996) “Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential,”Proc. Natl. Acad. Sci. USA, 93:14036-14040.
Fan et al., (1996) “A link between ferritin gene expression and ribonucleotide reductase R2 protein, as demonstrated by retroviral vector mediated stable expression of R2 cDNA,”FEBS Lett. 382:145-148.
Fan et al.,(1997) “The R1 component
Wright Jim A.
Young Aiping H.
Hopkins Susanne M.
Lorus Therapeutics Inc.
Nath Gary M.
The Nath Law Group
Zara Jane
LandOfFree
Antitumor antisense sequences directed against R1 and R2... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antitumor antisense sequences directed against R1 and R2..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antitumor antisense sequences directed against R1 and R2... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3963724